

FDA Public Workshop

Development of Safe and Effective Drug Therapies for CFS and ME

Speaker, Panelist and Moderator Disclosure Form

April 25 and 26, 2013


Dear Speaker, Panelist or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the Development of Safe and Effective Drug Therapies for Chronic Fatigue Syndrome and Myalgic Encephalomyelitis Public Workshop on April 25 and 26 in Bethesda, MD. This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.

Name of Meeting Participant: Bernard Munos

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions on use of drug products for Chronic Fatigue Syndrome or Myalgic Encephalomyelitis. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

I retired from Eli Lilly and Company in July 2010; I am a non-executive director of Glenmark Pharmaceuticals; I advise many organizations involved in biomedical research, none of which offers products or services targeted at CFS/ME patients; I speak frequently to a wide variety of audiences, both public and private, about biomedical innovation. I blog about innovation on the Forbes website.

Signature 

Please email the form to Mary Gross (mary.gross@fda.hhs.gov) by April 3. Speakers, we also request that you include this information as the second slide of your presentations.